Zata Pharmaceuticals Inc is developing a platform technology that enables a novel class of oligotherapeutics - synthetic compounds involved in the treatment of cancer, infections, and genetic diseases as well as in scarless wound healing. Founded by Dr. David R. Tabatdze and Dr. Paul Zamecnik, a co-discoverer of tRNA and a pioneer of oligotherapy (antisense chemotherapy). Zata has worked on development of a nucleic acid platform for the self-delivery of oligotherapeutics and has also developed antipathogen compounds capable of inactivating existing and emerging blood borne infectious agents in pre-transfusion blood products. ZATA is focused on two major programs: ZAP-D â Current blood safety approach is based on a large number of tests that do not provide 100% safety. ZAP-D (synthetic compound_ provides full safety by selective elimination of genomic molecules of the pathogens if presented in donated blood. ZATAâS OLIGOTHERAPEUTICS (OT). Cell membranes do not allow for the cellular uptake of negatively charged OT currently used. Low cellular penetration caused multiple OT to fail over the last couple of decades. ZATAâs technology solves this prob
